NCT02811861: A reported trial by Eisai Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02811861 |
|---|---|
| Title | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Oct. 13, 2016 |
| Completion date | Aug. 28, 2020 |
| Required reporting date | Aug. 28, 2021, midnight |
| Actual reporting date | Aug. 27, 2021 |
| Date last checked at ClinicalTrials.gov | Sept. 8, 2025 |
| Days late | None |